Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.17) per share which beat th

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),

Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in pre

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality w

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profi

Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and do

Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving av

Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving av

Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS act

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),

Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-

Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),

Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.

Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and cont

Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including prelimin

BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises

Investors need to pay close attention to BDTX stock based on the movements in the options market lat

Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and d

Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistanc

BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signa

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patientsTri

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX)

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock?

BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblasto

Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperfo

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.27) per share which missed

Piper Sandler analyst Kelsey Goodwin maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Ove

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improvin

Gainers Mobilicom Limited (NASDAQ: MOB) shares jumped 81.3% to $2.7187 after the company announc

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pr

Gainers Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 123% to $3.48 in pre-market trading

Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company

Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of sp

The Dow Jones closed lower by more than 500 points on Wednesday. Investors, meanwhile, focused on so

  During Monday's session, 101 companies made new 52-week lows.